other material
confidence high
sentiment neutral
materiality 0.55
Cara: $83M cash, royalty deal up to $40M, oral DFK Phase 3 readouts 2023-2026
Tvardi Therapeutics, Inc.
- Cash $83M as of Sep 30, 2023; royalty sale with HCRx for up to $40M ($37.5M expected Q4 2023).
- KORSUVA injection launched with CSL Vifor/Fresenius; approved in US, EU, Japan; TDAPA expires Mar 31, 2024.
- Oral DFK Phase 3: KIND1 AD topline Dec 2023; KICK1&2 CKD topline 2H2024; KOURAGE1 NP topline 2H2024.
- No debt, 54M shares outstanding, cash runway into 2025.